Latest News

ATLANTA — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place...
ATLANTA, Georgia — UCB, a global biopharmaceutical company, today announced that the final analysis of an open-label extension (OLE) study with the objective to describe long-term safety and effectiveness of FINTEPLA (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in Epilepsy & Behavior.2 No new or unexpected treatment-emergent adverse events (TEAEs) were reported.2 Children and adults...
Los Angeles, Calif. – Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma. CAR T-cell therapy uses genetically engineered versions of a...
Los Angeles, Calif. – A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted...